Mandatory Disclaimers on Dietary Supplements Do Not Reliably Communicate the Intended Issues

Kesselheim AS, Connolly JG, Rogers JR, Avorn J - Health Affairs

  • Regulation and Clinical Evidence

Summary:

In this systemic review of dietary supplement disclaimer studies, larger and more rigorous studies revealed that many consumers were unaware of disclaimers or that they did not affect patient perceptions of supplements. These findings suggest that relying on disclaimers as an alternative to government restrictions on drug marketing would be inadequate for informing patients about drug efficacy and safety, and risk enabling a return to problematic levels of inappropriate prescription drug use.

VIEW SOURCE

Recent Work from PORTAL

Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway

Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy

  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.

Politics and the Patient Encounter, in Dire Times

Avorn J - MedPage Today

  • Regulation and Clinical Evidence